Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Pregnancy Outcomes in Patients Treated with TNF Inhibitors

Michele B. Kaufman, PharmD, BCGP  |  Issue: March 2024  |  December 18, 2023

References

  1. Molto A, Ajrouche A, Tran D, et al. Continuing TNFi after pregnancy diagnosis in women with chronic rheumatic inflammatory diseases is not associated with worse obstetrical or infant outcomes and seems to reduce risk of maternal severe infection: The results of the emulated target trial BioC [abstract 0477]. Arthritis Rheumatol. 2023 Oct;75(suppl 9).

Page: 1 2 | Single Page
Share: 

Filed under:ACR ConvergenceBiologics/DMARDsConditionsDrug UpdatesMeeting Reports Tagged with:ACR Convergence 2023pregnancypregnant womentumor necrosis factor inhibitor (TNFi)

Related Articles

    A Better Family Plan

    October 1, 2007

    How to minimize the risks of pregnancy for women with SLE

    The Chimeric Self

    February 1, 2007

    Michrochimerism research offers insights into several autoimmune conditions

    Rheumatologists Should Discuss with Patients Use of Immunomodulatory Agents During Pregnancy

    November 16, 2016

    The decision to continue or discontinue immunomodulatory medications during pregnancy is a difficult one for both patients and physicians. On the one hand, when left untreated, rheumatic conditions can cause harm to an unborn child, as well as to the pregnant mother. On the other hand, medications can be harmful to a developing fetus. In…

    Treat to Target: Rheumatoid Arthritis in Pregnant Patients

    October 1, 2012

    A treat-to-target approach to managing rheumatoid arthritis can work even in pregnant women

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences